Alopecia News and Research

RSS

Alopecia is the lack or loss of hair from areas of the body where hair is usually found. Alopecia can be a side effect of some cancer treatments.

Simple DNA test can predict risk of bad side effects to thiopurine drugs

Screening a tiny section of DNA could help East Asian patients avoid severe reactions to some medications.

2 Jul 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

Baldness treatment using a medication for osteoporosis

According to researchers, a drug used to treat patients with osteoporosis may soon be helpful in treating baldness. The study was published in the latest issue of the journal PLOS Biology this week.

9 May 2018

Researchers make key discovery about cellular pathway linked to myriad of diseases

Researchers from the University of Dundee and the Francis Crick Institute have made a significant discovery about a cellular pathway associated with developmental defects and a myriad of diseases ranging from alopecia to colorectal cancer.

22 Mar 2018

African-American women with a common form of hair loss linked to greater risk for uterine fibroids

In a study of medical records gathered on hundreds of thousands of African-American women, Johns Hopkins researchers say they have evidence that women with a common form of hair loss have an increased chance of developing uterine leiomyomas, or fibroids.

29 Dec 2017

Novartis announces FDA approval of its first and only CML therapy with TFR data in product label

Novartis announced today that the US Food and Drug Administration (FDA) approved the inclusion of Treatment-free Remission (TFR) data in the Tasigna® (nilotinib) US product label.

26 Dec 2017

Researchers identify mechanism that regulates signaling events leading to cancer metastasis

Understanding how cancer cells are able to metastasize -- migrate from the primary tumor to distant sites in the body -- and developing therapies to inhibit this process are the focus of many laboratories around the country.

18 Dec 2017

Study reveals link of male-pattern baldness and premature graying with early heart disease

New research presented at the 69th Annual Conference of the Cardiological Society of India (CSI) indicated that premature greying and male-pattern baldness are linked to a greater than fivefold risk of heart disease before the age of 40. The study also suggested obesity is linked to a fourfold risk of early heart disease.

30 Nov 2017

FDA grants approval to first treatment for rare blood cancer

The U.S. Food and Drug Administration today expanded the approval of Zelboraf (vemurafenib) to include the treatment of certain adult patients with Erdheim-Chester Disease (ECD), a rare cancer of the blood.

7 Nov 2017

Cleveland Clinic selects Paxman Scalp Cooling System as one of top medical innovations for 2018

Paxman Scalp Cooling System has been named as one of Cleveland Clinic’s Top 10 Medical Innovations of 2018. The list of up-and-coming technologies was selected by a panel of Cleveland Clinic physicians and scientists and was announced at a presentation at the 2017 Medical Innovation Summit.

From Paxman 1 Nov 2017

USC scientists obtain molecular 'how to' guide for growing hair

How does the skin develop follicles and eventually sprout hair? A USC-led study, published in the Proceedings of the National Academy of Sciences (PNAS), addresses this question using insights gleaned from organoids, 3D assemblies of cells possessing rudimentary skin structure and function--including the ability to grow hair.

11 Aug 2017

Ground-breaking new breast cancer drugs have manageable toxicity profile for most patients

A ground-breaking new class of oral drugs for treating breast cancer, known as cyclin-dependent kinase (CDK) inhibitors, are generally well-tolerated, with a manageable toxicity profile for most patients.

13 Jul 2017

FDA expands use of cooling cap to minimize chemotherapy-induced hair loss in cancer patients

Today, the U.S. Food and Drug Administration cleared the expanded use of a cooling cap, DigniCap Cooling System, to reduce hair loss (alopecia) during chemotherapy.

3 Jul 2017

Women pay 40% more than men for common hair loss medication, study finds

Women pay an average of 40 percent more than men for minoxidil foams – a hair loss remedy most commonly known as Rogaine – according to a new analysis from researchers at the Perelman School of Medicine at the University of Pennsylvania.

8 Jun 2017

Paxman to showcase FDA approved scalp cooler for chemotherapy induced alopecia at ASCO

A pioneering scalp cooling treatment that prevents alopecia in breast cancer patients undergoing chemotherapy will be showcased at the American Society of Clinical Oncology (ASCO) for the first time since gaining FDA clearance.

From Paxman 19 May 2017

Study reveals promising results for primary liver cancer patients treated with SIR-Spheres Y-90 resin microspheres

Patients with advanced or inoperable Hepatocellular Carcinoma (HCC) who usually received one or two treatments with liver-directed SIR-Spheres Y-90 resin microspheres in the 459-patient French SARAH study had similar survival compared to patients who received standard twice-daily systemic treatment with sorafenib, but with less than half the number and significantly fewer severe treatment-related adverse effects and significantly better Quality of Life, according to data presented here at The International Liver Congress™ 2017.

26 Apr 2017

Scalp cooling technology to fight cancer causing alopecia (hair loss) approved by the FDA

Paxman Coolers Limited announced today that The U.S. Food and Drug Administration (FDA) has cleared the company to market the Paxman Scalp Cooling System, a scalp cooling technology that was developed by a British family to reduce hair loss in breast cancer patients undergoing chemotherapy.

From Paxman 19 Apr 2017

Use of 5ARIs for prostatic enlargement not linked to increased suicide risk in older men

Using 5α- reductase inhibitors was not associated with increased suicide risk in a group of older men but risks for self-harm and depression were increased during the 18 months after medication initiation, although "the relatively small magnitude of these risks should not dissuade physicians from prescribing these medications in appropriate patients," according to an article published online by JAMA Internal Medicine.

20 Mar 2017

Hair loss prevention device for breast cancer patients showcased by Paxman at Vienna conference

A pioneering scalp cooling treatment that prevents alopecia in early stage breast cancer patients undergoing chemotherapy will be showcased at the 15th St. Gallen International Breast Cancer Conference, Vienna.

From Paxman 15 Mar 2017

Prolonged exposure to male hormone blockers increases risk of persistent erectile dysfunction

Men with longer exposure to the drugs finasteride and dutasteride had a higher risk of getting persistent erectile dysfunction than men with less exposure, reports a new Northwestern Medicine study.

9 Mar 2017